A collection of independent reports relevant to Radient Pharma's research in cancer diagnostics and treatment

• Ovarian Carcinoma: Clinical Validity Simultaneous Determination of FDP with DR-70® (FDP) ELISA and CA-125
  German Journal of Obstetrics and Gynecology, January 2006
• Serum Concentration of DR-70® (FDP) ELISA for Carcinoma of the Tongue
  British Journal of Oral and Maxillofacial Surgery, November 2004
• Elevated Fibrinogen-Fibrin Degradation Products (FDP) in Serum of Colorectal Cancer Patients
  Analytical Letters, Vol. 37 No. 14, 2004 (PDF, 2 MB)
• The new DR-70® (FDP) ELISA immunoassay detects cancer of the gastrointestinal tract
  August 2004 (PDF, 192 KB)
• Sensitivity & Specificity of DR-70® (FDP) ELISA Lung Cancer Immunoassay
  Analytical Letters, Vol. 32 No. 7, January 1999 (PDF, 372 KB)
• Granulocyte-Macrophage Colony-Stimulating Factor and B7-2 Combination Immunogene Therapy in an Allogeneic Hu-PBL-SCID/Beige Mouse–Human Glioblastoma Multiforme Model
  Human Gene Therapy, June 10, 1997